

Kallyope, Novo Nordisk tie up to treat diabetes, obesity

19 June 2018 | News

Kallyope will receive an upfront payment and research support for activities conducted in the collaboration.



Kallyope Inc. and Novo Nordisk A/S have entered into a research collaboration and option agreement to discover novel peptide therapeutics to treat obesity and diabetes.

Kallyope will receive an upfront payment and research support for activities conducted in the collaboration. Under the terms of the agreement, Novo Nordisk has an option to license exclusive worldwide rights to develop and commercialize up to six products discovered in the collaboration.

Kallyope will receive a license fee if Novo Nordisk chooses to exercise an option to a therapeutic discovered and validated in the joint research plan and potential research, development, and sales milestones. In addition, Kallyope will receive royalties on worldwide product sales of licensed products.

Kallyope has developed an innovative platform to interrogate the gut-brain axis and discover new medicines in multiple therapeutic areas. The platform integrates single-cell sequencing, bioinformatics, functional and anatomical circuit mapping, and organoids. It has enabled the discovery of new biological mechanisms, including multiple potential secreted products from the gut-brain axis that may play a role in metabolism.

Under a joint research plan, Kallyope and Novo Nordisk will collaborate on *in vitro* and *in vivo* studies to validate a number of product candidates. Following validation and option exercise, Novo Nordisk will assume responsibility for further preclinical and clinical development, manufacturing, and commercialization.